Christian Nolet
About Christian Nolet
Independent director of Jasper Therapeutics since 2021; Age 68; Class III director with current term expiring at the 2027 annual meeting. Former audit partner (EY 2001–2019; previously PwC 1991–2001), retired CPA (CA), and recognized “audit committee financial expert.” He is independent under Nasdaq rules and brings >40 years of audit and life sciences governance experience.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ernst & Young LLP (EY) | Audit Partner; Leader, West EY Life Sciences Industry Group | 2001–2019 | Led sector practice; senior audit leadership for life sciences clients |
| PricewaterhouseCoopers LLP | Partner | 1991–2001 | Audit partner roles |
| California Life Sciences (industry association) | Executive Committee; Finance Committee Chair | 2000–Feb 2024 | Long-serving governance and finance leadership in industry association |
| Biotechnology Innovation Organization (BIO) | Finance & Investment Committee; Emerging Companies Section | Not specified | Policy/industry engagement roles |
External Roles
| Company | Role | Public/Private | Tenure |
|---|---|---|---|
| ArriVent Biopharma, Inc. (AVBP) | Director | Public | Since Sep 2023 (current) |
| Revance Therapeutics, Inc. (RVNC) | Director | Public | Jul 2019–Feb 2025 (to acquisition) |
| PolarityTE, Inc. (PTE) | Director | Public | Apr 2020–Jan 2023 |
| Ambrx Biopharma Inc. (AMAM) | Director | Public | Jan 2021–Nov 2021 |
| Viela Bio, Inc. (VIE) | Director | Public | Aug 2019–Mar 2021 (to acquisition) |
Board Governance
- Independence: Determined independent by the Board under SEC/Nasdaq rules; Jasper board is majority independent.
- Committee assignments: Chair, Audit Committee; Chair, Compensation Committee; member of both committees. Designated “audit committee financial expert.”
- Tenure/class: Director since 2021; Class III; term through 2027 annual meeting.
- Attendance: Each director attended ≥75% of Board/committee meetings in 2024; Board met 6x (plus 3 written consents); Audit 5x; Compensation 4x.
- Board structure: Non-employee Chair (Tom Wiggans); independent directors meet in executive session after regular Board meetings.
- Compensation advisor independence: Compensation Committee uses Alpine Rewards; committee determined no conflicts.
Fixed Compensation
| Component (2024) | Amount ($) |
|---|---|
| Board annual retainer (member) | $40,000 |
| Audit Committee chair fee | $15,000 |
| Compensation Committee chair fee | $10,000 |
| Total cash fees earned (disclosed) | $65,000 |
- Policy uses retainers (no meeting fees); earned quarterly in arrears.
Performance Compensation
| Equity Element (2024) | Detail |
|---|---|
| Option awards (grant-date fair value) | $161,489 |
| Outstanding options at 12/31/2024 | 20,004 shares |
| Annual grant design | Annual director stock options vest in full on first anniversary of grant date; effective Apr 19, 2024 annual grant size increased to 7,500 options (from 4,700 pre-Apr 19, 2024). |
| New director one-time grant | Effective Apr 19, 2024 increased to 15,000 options; 25% vests at 1 year, remainder monthly over 36 months. |
Director equity is time-based; no performance metrics are tied to director awards.
Other Directorships & Interlocks
- Current public company board: ArriVent Biopharma (AVBP).
- Recent public boards: Revance (RVNC), PolarityTE (PTE), Ambrx (AMAM), Viela Bio (VIE).
- No JSPR-related party transactions disclosed involving Mr. Nolet; related-party disclosure in 2024–2025 period pertains to another director (Dr. Shizuru consulting).
Expertise & Qualifications
- Retired CPA (California); former EY and PwC audit partner with deep life sciences coverage.
- Board-designated audit committee financial expert.
- Industry governance experience via California Life Sciences executive/finance committees and BIO committees.
Equity Ownership
| As of April 30, 2025 | Shares |
|---|---|
| Total beneficial ownership | 23,254 (includes 3,250 directly held; 20,004 options exercisable within 60 days) |
| Percent of shares outstanding | <1% (*) |
- Company policy prohibits directors/employees/consultants from hedging or pledging JSPR securities.
Governance Assessment
- Strengths: Independent; chairs Audit and Compensation; designated financial expert; strong attendance; majority-independent board with non-employee Chair; insider-trading policy bans hedging/pledging; clawback policy aligned with SEC/Nasdaq Rule 10D-1.
- Watch items: Concentration of committee leadership (Audit and Compensation chaired by the same director), which some investors scrutinize for workload/independence optics; ensure continued high attendance and engagement given external board commitments. (Committee chair roles and meeting loads as disclosed)
